![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
20
Hetero Labs Limited Hyderabad In, based in India, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their significant offerings is Valsartan, Process III, supported by a 'Withdrawn by Holder' Certificate of Suitability (CEP) with the number R1-CEP 2016-069 - Rev 00
This Chemical Type CEP, issued on January 20, 2022, remains in force until July 12, 2022, ensuring its reliability within the pharmaceutical industry.
Substance Number 2423 associated with this CEP further emphasizes